力尔凡联合氟尿嘧啶腹腔化疗对腺癌并顽固性腹水的临床效果

Clinical Effectiveness of Lifein Combined with Fluorouracil in Curing Advanced Adenocarcinoma with Refractory Ascites

目的观察力尔凡联合氟尿嘧啶腹腔留置管灌注化疗对晚期腺癌合并顽固性腹水的治疗效果及不良反应。方法将63例腺癌合并顽固性腹水患者随机分为A组(n=32)和B组(n=31),A组采用力尔凡联合氟尿嘧啶腹腔灌注化疗;B组采用氟尿嘧啶腹腔灌注化疗。观察2组临床疗效及不良反应发生情况。结果总有效率A组84.38%,B组64.51%,2组比较,差异有统计学意义(P<0.01);A组腹痛发生率、腹腔化疗所致白细胞下降发生率均显著低于B组,2组比较,差异均有统计学意义(均P<0.01)。结论力尔凡联合氟尿嘧啶腹腔留置管灌注化疗方法简单,对晚期腺癌并顽固性腹水疗效确切,但其操作过程讲究一定的技巧;力尔凡能减少氟尿嘧啶的部分化疗并发症。

Objective To study the effectiveness and side-effect of peritoneal perfusion chemotherapy using lifein combined with fluorouracil in curing end-staged adenocarcinoma complicated by consistent pyoperitoneum. Methods Sixty three patients with end-staged adenocarcinoma complicated by consistent pyoperitoneum are randomly divided in to group A：peritoneal perfusion chemotherapy using lifein combined with fluorouracil （n=32）, and group B： peritoneal p erfusion chemotherapy using fluorouracil alone （n=31）,then compare the two groups in respect of effec- tiveness and side-effect. Results Overall effective rates of group A and group B are 84.38 % and 64.52% respectively（P〈0.01）,while the occurrence of abdominal pain and descending white blood cell level resulted from peritoneal chemotherapy in group A patients is statistically lower than group B （all P〈0.01）. Conclusion Peritoneal perfusion chemotherapy using lifein combined with fluorouracil is a simple and effective but relatively technically challenging therapy for end-staged adenocarcinoma complieated by consistent pyoperitoneum. Lifein can reduce the inc dence of part of the complication associated with fluorouracil.